Journal of Gastroenterology

, Volume 52, Issue 3, pp 301–307 | Cite as

Factors associated with poor therapeutic response in outpatients with irritable bowel syndrome: a multicenter study in Japan

  • Eiji Yamada
  • Seishi Tsunoda
  • Tsuyoshi Abe
  • Eri Uchida
  • Hiromichi Teraoka
  • Seitaro Watanabe
  • Ichiro Kawana
  • Masataka Tagri
  • Noriomi Hosaka
  • Kazuki Nagai
  • Haruo Nishino
  • Atsushi NakajimaEmail author
Original Article—Alimentary Tract



Some patients with irritable bowel syndrome (IBS) show poor response to treatment. However, risk factors associated with poor therapeutic response have not been determined.


This multicenter trial evaluated consecutive outpatients with IBS undergoing treatment for more than 1 month. Mental health status and physical function were evaluated using the Japanese version of the SF-8. Therapeutic response was evaluated using the IBS severity index-Japanese version (IBS-SIJ). Patients with IBS-SIJ scores ≥175 were defined as poor responders to treatment, whereas those with IBS-SIJ scores <175 were defined as good responders. The demographic and clinical characteristics of these two groups, along with medications, were compared.


The study enrolled 131 participants, 75 with IBS-SIJ scores ≥175–56 with IBS-SIJ scores <175. Multiple logistic regression analysis showed that female sex [odds ratio (OR) 2.67, 95 % confidence interval (CI) 1.19–5.97, p = 0.0167] and mental component summary (MCS) of the SF-8 <40 (OR 2.58, 95 % CI 1.12–5.97, p = 0.0263) were independent risk factors for poor therapeutic response in patients with IBS.


Lower MCS and female sex were risk factors for poor therapeutic response in patients with IBS. Ascertaining the mechanisms by which lower MCS and female sex are associated with poor therapeutic response in IBS may help design better treatments (Trial registration number: UMIN000016804).


Irritable bowel syndrome Poor therapeutic response Mental health 



Irritable bowel syndrome


Body mass index


Gastroesophageal reflux disease


Functional dyspepsia


Physical component summary


Mental component summary


Proton pump inhibitor


Non-steroidal anti-inflammatory drug


Quality of life


Poor therapeutic response group



The authors thank the nurses and staff of all centers for their help in collecting data.

Complicance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Declaration of funding interests



  1. 1.
    Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 2005;34:189–204.CrossRefPubMedGoogle Scholar
  2. 2.
    Talley NJ. Irritable bowel syndrome. Intern Med J. 2006;36:724–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Spiller R, Aziz Q, Creed F. Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56:1770–98.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Fukudo S, Kaneko H, Akiho H, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50:11–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150:358–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Fukuhara S, Suzukamo Y. Manual of the SF-8. Japanese ed. Kyoto: Institute for health outcomes and process evaluation research; 2004.Google Scholar
  7. 7.
    Sanderson K, Andrews G. Prevalence and severity of mental health-related disability and relationship to diagnosis. Psychiatr Serv. 2002;53:80–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Riegler G, Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech Coloproctol. 2001;5:163–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Shinozaki M, Kanazawa M, Sagami Y, et al. Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index. J Gastroenterol. 2006;41:491–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395–402.CrossRefPubMedGoogle Scholar
  12. 12.
    Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149–59.CrossRefPubMedGoogle Scholar
  14. 14.
    Mueller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2000;15:1655–66.CrossRefGoogle Scholar
  15. 15.
    Creed F. The relationship between psychosocial parameters and outcome in irritable bowel syndrome. Am J Med. 1999;107:74S–80S.CrossRefPubMedGoogle Scholar
  16. 16.
    Ustün TB. Cross-national epidemiology of depression and gender. J Gend Specif Med. 2000;3:54–8.PubMedGoogle Scholar
  17. 17.
    Svedlund J, Ottosson JO, Sjödin I, et al. Controlled study of psychotherapy in irritable bowel syndrome. Lancet. 1983;322:589–92.CrossRefGoogle Scholar
  18. 18.
    Gonsalkorale WM, Miller V, Afzal A, et al. Long-term benefits of hypnotherapy for irritable bowel syndrome. Gut. 2003;52:1623–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Halder SL, Locke GR 3rd, Schleck CD, et al. Natural history of functional gastrointestinal disorders: a 12–year longitudinal population-based study. Gastroenterology. 2007;133:799–807.CrossRefPubMedGoogle Scholar
  20. 20.
    Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 2010;25:1151–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Kennedy T, Jones R, Darnley S, et al. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ. 2005;331:435.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Carruthers HR, Miller V, Morris J, et al. Using art to help understand the imagery of irritable bowel syndrome and its response to hypnotherapy. Int J Clin Exp Hypn. 2009;57:162–73.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2016

Authors and Affiliations

  • Eiji Yamada
    • 1
  • Seishi Tsunoda
    • 2
  • Tsuyoshi Abe
    • 3
  • Eri Uchida
    • 4
  • Hiromichi Teraoka
    • 5
  • Seitaro Watanabe
    • 1
  • Ichiro Kawana
    • 1
  • Masataka Tagri
    • 6
  • Noriomi Hosaka
    • 7
  • Kazuki Nagai
    • 8
  • Haruo Nishino
    • 9
  • Atsushi Nakajima
    • 10
    Email author
  1. 1.Gastroenterology DivisionSaiseikai Yokohama-shi Nanbu HospitalYokohamaJapan
  2. 2.Tsunoda IinYokohamaJapan
  3. 3.Abe ClinicSagamiharaJapan
  4. 4.Gastroenterology DivisionChigasaki Municipal HospitalChigasakiJapan
  5. 5.Teraoka ClinicYokohamaJapan
  6. 6.Department of Biostatistics and EpidemiologyYokohama City University School of MedicineYokohamaJapan
  7. 7.Hikari ClinicYokohamaJapan
  8. 8.Nagai ClinicYokohamaJapan
  9. 9.Matsushima ClinicYokohamaJapan
  10. 10.Department of Gastroenterology and HepatologyYokohama City University School of MedicineYokohamaJapan

Personalised recommendations